Maravai Life Sciences

What Maravai Life Sciences does

Maravai Life Sciences is a publicly traded (NASDAQ: MRVI) life sciences company headquartered in San Diego, California, founded in 2014 and controlled by GTCR as majority shareholder. It provides critical reagents, enzymes, and services that enable drug therapy, diagnostics, and novel vaccine development, serving biopharmaceutical manufacturers, biotech companies, academic and government research institutions, and other contract development and manufacturing organizations (CDMOs) globally across 181 countries. The company operates through four sub-brands: TriLink BioTechnologies (mRNA and nucleic acid products plus CDMO services, including the proprietary CleanCap mRNA capping technology used in the world's first FDA-approved mRNA vaccine with 5+ billion doses shipped), Cygnus Technologies (bioprocess impurity detection kits, including HCP ELISA kits used in all 29 approved CAR-T therapies), Glen Research (DNA/RNA nucleotide synthesis reagents for oligonucleotide-based therapeutics and diagnostics), and Alphazyme (custom molecular biology enzymes for diagnostics and research applications). The combined portfolio exceeds 3,500 products.

The company's core technologies include CleanCap (a proprietary mRNA capping reagent), CleanScribe (RNA polymerase), and ModTail (poly(A) tail technology), supported by manufacturing capabilities certified under ISO 9001:2015, ISO 13485, and FDA cGMP. Maravai monetizes through direct B2B sales (quotes and contracts), distributor partnerships, and e-commerce channels, with revenue generated across nucleic acid products, CDMO services, biologics safety testing, and enzyme products. The company has 501–1,000 employees and reported 2025 revenue of $185.7M, with 2026 guidance of $205–215M reflecting a partial rebound from the 2024 post-COVID commercial vaccine wind-down.

Name

Maravai Life Sciences

Legal name

Maravai Intermediate Holdings, LLC

Website

https://maravai.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Maravai Life Sciences is a publicly traded (NASDAQ: MRVI) provider of nucleic acid products, enzymes, CDMO services, and biologics safety testing. It serves biopharmaceutical, biotech, academic, and government customers globally through four brands: TriLink, Cygnus, Glen Research, and Alphazyme.

Ownership category

akta.pro rank

Product category

Life Sciences Reagents and CDMO Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

akta.pro secondary industries

mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF), Plasmid DNA & mRNA Manufacturing Services (HLAAAKAE), RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF), mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

Keywords

• Nucleic acid manufacturing
• MRNA capping technology
• Biologics safety testing
• Oligonucleotide synthesis reagents
• CDMO services

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Nucleic Acid Products: Sale of nucleic acid products including nucleotides, modified nucleotides, CleanCap® capping technology, CleanAmp® hot start PCR reagents, and custom oligonucleotide synthesis products. Revenue generated from product sales to biotech, biopharma, and research institutions.
2. CDMO Services: Contract development and manufacturing organization (CDMO) services providing clinical manufacturing capabilities for mRNA therapeutics. TriLink offers CDMO services including GMP manufacturing, process development, and analytical services for nucleic acid therapies.
3. Biologics Safety Testing Products: Sale of impurity detection assays including HCP ELISA kits, viral clearance kits (MockV®), and endotoxin testing solutions for biopharmaceutical development and lot release testing.
4. Enzyme Products: Sale of molecular biology enzymes including CleanScribe™ RNA Polymerase, EndonucleaseGTP®, and custom enzymes for mRNA synthesis, sequencing, and molecular diagnostics through Alphazyme brand.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Maravai Life Sciences provides critical products and services that enable the development of drug therapies, diagnostics, and novel vaccines, operating through four brands: TriLink BioTechnologies (mRNA and nucleic acid solutions including proprietary CleanCap® capping technology and CDMO services), Cygnus Technologies (bioprocess impurity detection assays and biologics safety testing), Glen Research (DNA/RNA nucleotide synthesis supplies and oligonucleotide materials), and Alphazyme (custom industrial-scale molecular biology enzymes). The portfolio includes more than 3,500 products spanning modified nucleotides, capping reagents, RNA polymerases, purification tools, viral clearance kits, and HCP ELISA assays, sold to biopharmaceutical, biotech, CDMO, research, and government customers globally.

Product overview

Maravai LifeSciences operates as a diversified life sciences reagents and services company with four primary sub-brands: TriLink BioTechnologies (mRNA and nucleic acid solutions including CleanCap® capping technology), Cygnus Technologies (bioprocess impurity detection and analytics), Glen Research (DNA/RNA nucleotide synthesis supplies), and Alphazyme (custom molecular biology enzymes). The portfolio includes more than 3,500 products spanning proprietary technologies like CleanCap® (used in FDA-approved mRNA vaccines), CleanScribe™ RNA Polymerase (for reduced dsRNA formation), ModTail™ (for enhanced protein expression), MockV® RVLP Kits (for viral clearance testing), CleanAmp® hot start PCR, Glen Pak™ purification products, and PROTEIN A MIX-N-GO™. The company provides CDMO services through TriLink and serves pharmaceutical, biotech, and life sciences companies globally.

Differentiator

Problem solved

Functional benefit

Brands

• TriLink BioTechnologies: Global leader in nucleic acid and mRNA solutions for over 25 years, delivering CDMO services and high-quality ready-made and custom products including proprietary CleanCap mRNA capping technology.
• Cygnus Technologies
• Glen Research
• Alphazyme

Quantifiable outcome

• 5+ billion vaccine doses shipped globally using CleanCap technology
• +7 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core and strategic.

• Officinae BiocoreStrategic or Co-development Partner · 1 February 2025Maravai LifeSciences completed acquisition of the DNA and RNA business of Officinae Bio in February 2025, expanding capabilities in nucleic acid therapies. The co-founder Davide De Lucrezia joined Maravai as Senior Vice President, Digital Innovation, Products & Marketing.
• Molecular AssembliescoreStrategic or Co-development Partner · 1 January 2025Maravai acquired assets and intellectual property from Molecular Assemblies in January 2025, strengthening its nucleic acid synthesis capabilities and IP portfolio.
• Applied DNA SciencesstrategicStrategic or Co-development Partner · 1 June 2024Applied DNA and Alphazyme concluded Linea™ RNAP manufacturing scale-up project, delivering substantial improvement in Linea IVT platform economics. Alphazyme is Maravai's enzyme production brand.
• Johns Hopkins UniversitystrategicStrategic or Co-development Partner · 1 May 2024TriLink BioTechnologies collaborated with Johns Hopkins University to establish a new RNA Innovation Center, supporting RNA research and development initiatives.
• MyChem LLCcoreStrategic or Co-development Partner · 28 January 2022Maravai acquired nucleotide manufacturer MyChem for $240 million in cash in January 2022, expanding nucleotide manufacturing capabilities. MyChem was co-founded by Chanfeng Zhao who joined TriLink as Chief Scientific Officer.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Bio-Techne: Bio-Techne is a direct peer through its nucleic acid research reagents, mRNA synthesis products, and protein analysis tools, directly competing with Maravai's TriLink, Glen Research, and Alphazyme brands in the same biopharma and academic customer base.
• Aldevron (Danaher): Aldevron, now part of Danaher, is one of the closest direct peers to TriLink, offering plasmid DNA, mRNA, and protein CDMO services to biotech and biopharma developers — directly overlapping with Maravai's nucleic acid manufacturing and CDMO offerings.
• GenScript: GenScript competes directly with Maravai's nucleic acid and mRNA offerings through its gene synthesis, oligonucleotide manufacturing, and mRNA production services, serving similar biotech and biopharma customers.

Broad incumbents

• Lonza Group: Lonza is a global CDMO incumbent with a substantially larger biologics and nucleic acid manufacturing footprint; it competes with TriLink's CDMO services and serves overlapping biopharma customers in mRNA, gene therapy, and biologics.
• Samsung Biologics: Samsung Biologics is a large-scale CDMO incumbent expanding into mRNA and nucleic acid manufacturing, competing with TriLink for commercial-scale mRNA contracts and increasingly overlapping on biologics safety testing through partner networks.
• MilliporeSigma (BioReliance): MilliporeSigma's BioReliance biopharma services and viral/gene therapy CDMO operations directly compete with both TriLink's CDMO services and Cygnus's safety testing products across overlapping biopharma customers.
• Eurofins Scientific: Eurofins competes with Cygnus Technologies in biologics safety testing, viral clearance, and HCP analytics, and offers broader biopharma testing services overlapping with Maravai's biologics safety testing segment.
• Thermo Fisher Scientific: Thermo Fisher is a broad life sciences incumbent with overlapping nucleic acid reagents, enzymes, and CDMO services that compete across Maravai's full product portfolio; it also offers the kind of integrated IVT and GMP enzyme capabilities that Maravai is building toward.
• QIAGEN: QIAGEN competes with Glen Research and TriLink in molecular biology reagents, enzymes, and nucleic acid purification products, and overlaps with Maravai's diagnostic and molecular biology customer segments.

Emerging players

• Codexis: Codexis is an emerging enzyme engineering player whose engineered RNA polymerases and nucleoside production technology compete with Alphazyme's custom enzyme offerings and TriLink's IVT reagent stack in the same nucleic acid manufacturing value chain.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/maravai-lifesciences

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries6 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maravai Life Sciences